Factor XII inhibition reduces thrombus formation in a primate thrombosis model

Anton Matafonov, Philberta Y. Leung, Adam E. Gailani, Stephanie L. Grach, Cristina Puy, Qiufang Cheng, Mao Fu Sun, Owen J T McCarty, Erik I. Tucker, Hiroaki Kataoka, Thomas Renné, James H. Morrissey, Andras Gruber, David Gailani

    Research output: Contribution to journalArticle

    114 Citations (Scopus)

    Abstract

    The plasma zymogens factor XII (fXII) and factor XI (fXI) contribute to thrombosis in a variety of mouse models. These proteins serve a limited role in hemostasis, suggesting that antithrombotic therapies targeting them may be associated with low bleeding risks. Although there is substantial epidemiologic evidence supporting a role for fXI in human thrombosis, the situation is not as clear for fXII. We generated monoclonal antibodies (9A2and15H8) against the human fXII heavy chain that interfere with fXII conversion to the protease factor XIIa (fXIIa). The anti-fXII antibodies were tested in models in which anti-fXI antibodies are known to have antithrombotic effects. Both anti-fXII antibodies reduced fibrin formation in human blood perfused through collagen-coated tubes. fXII-deficient mice are resistant to ferric chloride-induced arterial thrombosis, and this resistance can be reversed by infusion of human fXII. 9A2 partially blocks, and 15H8 completely blocks, the prothrombotic effect of fXII in this model. 15H8 prolonged the activated partial thromboplastin time of baboon and human plasmas. 15H8 reduced fibrin formation in collagen-coated vascular grafts inserted into arteriovenous shunts in baboons, and reduced fibrin and platelet accumulation downstream of the graft. These findings support a role for fXII in thrombus formation in primates.

    Original languageEnglish
    Pages (from-to)1739-1746
    Number of pages8
    JournalBlood
    Volume123
    Issue number11
    DOIs
    Publication statusPublished - 13 Mar 2014

    Fingerprint

    Factor XII
    Primates
    Thrombosis
    Factor XI
    Fibrin
    Papio
    Human engineering
    Grafts
    Antibodies
    Collagen
    Factor XIIa
    Plasma (human)
    Transplants
    Enzyme Precursors
    Partial Thromboplastin Time
    Thromboplastin
    Platelets
    Hemostasis
    Blood Vessels
    Blood

    ASJC Scopus subject areas

    • Hematology
    • Biochemistry
    • Cell Biology
    • Immunology

    Cite this

    Matafonov, A., Leung, P. Y., Gailani, A. E., Grach, S. L., Puy, C., Cheng, Q., ... Gailani, D. (2014). Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood, 123(11), 1739-1746. https://doi.org/10.1182/blood-2013-04-499111

    Factor XII inhibition reduces thrombus formation in a primate thrombosis model. / Matafonov, Anton; Leung, Philberta Y.; Gailani, Adam E.; Grach, Stephanie L.; Puy, Cristina; Cheng, Qiufang; Sun, Mao Fu; McCarty, Owen J T; Tucker, Erik I.; Kataoka, Hiroaki; Renné, Thomas; Morrissey, James H.; Gruber, Andras; Gailani, David.

    In: Blood, Vol. 123, No. 11, 13.03.2014, p. 1739-1746.

    Research output: Contribution to journalArticle

    Matafonov, A, Leung, PY, Gailani, AE, Grach, SL, Puy, C, Cheng, Q, Sun, MF, McCarty, OJT, Tucker, EI, Kataoka, H, Renné, T, Morrissey, JH, Gruber, A & Gailani, D 2014, 'Factor XII inhibition reduces thrombus formation in a primate thrombosis model', Blood, vol. 123, no. 11, pp. 1739-1746. https://doi.org/10.1182/blood-2013-04-499111
    Matafonov A, Leung PY, Gailani AE, Grach SL, Puy C, Cheng Q et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood. 2014 Mar 13;123(11):1739-1746. https://doi.org/10.1182/blood-2013-04-499111
    Matafonov, Anton ; Leung, Philberta Y. ; Gailani, Adam E. ; Grach, Stephanie L. ; Puy, Cristina ; Cheng, Qiufang ; Sun, Mao Fu ; McCarty, Owen J T ; Tucker, Erik I. ; Kataoka, Hiroaki ; Renné, Thomas ; Morrissey, James H. ; Gruber, Andras ; Gailani, David. / Factor XII inhibition reduces thrombus formation in a primate thrombosis model. In: Blood. 2014 ; Vol. 123, No. 11. pp. 1739-1746.
    @article{b0718c91aa9a4cf987a59bf0e491d600,
    title = "Factor XII inhibition reduces thrombus formation in a primate thrombosis model",
    abstract = "The plasma zymogens factor XII (fXII) and factor XI (fXI) contribute to thrombosis in a variety of mouse models. These proteins serve a limited role in hemostasis, suggesting that antithrombotic therapies targeting them may be associated with low bleeding risks. Although there is substantial epidemiologic evidence supporting a role for fXI in human thrombosis, the situation is not as clear for fXII. We generated monoclonal antibodies (9A2and15H8) against the human fXII heavy chain that interfere with fXII conversion to the protease factor XIIa (fXIIa). The anti-fXII antibodies were tested in models in which anti-fXI antibodies are known to have antithrombotic effects. Both anti-fXII antibodies reduced fibrin formation in human blood perfused through collagen-coated tubes. fXII-deficient mice are resistant to ferric chloride-induced arterial thrombosis, and this resistance can be reversed by infusion of human fXII. 9A2 partially blocks, and 15H8 completely blocks, the prothrombotic effect of fXII in this model. 15H8 prolonged the activated partial thromboplastin time of baboon and human plasmas. 15H8 reduced fibrin formation in collagen-coated vascular grafts inserted into arteriovenous shunts in baboons, and reduced fibrin and platelet accumulation downstream of the graft. These findings support a role for fXII in thrombus formation in primates.",
    author = "Anton Matafonov and Leung, {Philberta Y.} and Gailani, {Adam E.} and Grach, {Stephanie L.} and Cristina Puy and Qiufang Cheng and Sun, {Mao Fu} and McCarty, {Owen J T} and Tucker, {Erik I.} and Hiroaki Kataoka and Thomas Renn{\'e} and Morrissey, {James H.} and Andras Gruber and David Gailani",
    year = "2014",
    month = "3",
    day = "13",
    doi = "10.1182/blood-2013-04-499111",
    language = "English",
    volume = "123",
    pages = "1739--1746",
    journal = "Blood",
    issn = "0006-4971",
    publisher = "American Society of Hematology",
    number = "11",

    }

    TY - JOUR

    T1 - Factor XII inhibition reduces thrombus formation in a primate thrombosis model

    AU - Matafonov, Anton

    AU - Leung, Philberta Y.

    AU - Gailani, Adam E.

    AU - Grach, Stephanie L.

    AU - Puy, Cristina

    AU - Cheng, Qiufang

    AU - Sun, Mao Fu

    AU - McCarty, Owen J T

    AU - Tucker, Erik I.

    AU - Kataoka, Hiroaki

    AU - Renné, Thomas

    AU - Morrissey, James H.

    AU - Gruber, Andras

    AU - Gailani, David

    PY - 2014/3/13

    Y1 - 2014/3/13

    N2 - The plasma zymogens factor XII (fXII) and factor XI (fXI) contribute to thrombosis in a variety of mouse models. These proteins serve a limited role in hemostasis, suggesting that antithrombotic therapies targeting them may be associated with low bleeding risks. Although there is substantial epidemiologic evidence supporting a role for fXI in human thrombosis, the situation is not as clear for fXII. We generated monoclonal antibodies (9A2and15H8) against the human fXII heavy chain that interfere with fXII conversion to the protease factor XIIa (fXIIa). The anti-fXII antibodies were tested in models in which anti-fXI antibodies are known to have antithrombotic effects. Both anti-fXII antibodies reduced fibrin formation in human blood perfused through collagen-coated tubes. fXII-deficient mice are resistant to ferric chloride-induced arterial thrombosis, and this resistance can be reversed by infusion of human fXII. 9A2 partially blocks, and 15H8 completely blocks, the prothrombotic effect of fXII in this model. 15H8 prolonged the activated partial thromboplastin time of baboon and human plasmas. 15H8 reduced fibrin formation in collagen-coated vascular grafts inserted into arteriovenous shunts in baboons, and reduced fibrin and platelet accumulation downstream of the graft. These findings support a role for fXII in thrombus formation in primates.

    AB - The plasma zymogens factor XII (fXII) and factor XI (fXI) contribute to thrombosis in a variety of mouse models. These proteins serve a limited role in hemostasis, suggesting that antithrombotic therapies targeting them may be associated with low bleeding risks. Although there is substantial epidemiologic evidence supporting a role for fXI in human thrombosis, the situation is not as clear for fXII. We generated monoclonal antibodies (9A2and15H8) against the human fXII heavy chain that interfere with fXII conversion to the protease factor XIIa (fXIIa). The anti-fXII antibodies were tested in models in which anti-fXI antibodies are known to have antithrombotic effects. Both anti-fXII antibodies reduced fibrin formation in human blood perfused through collagen-coated tubes. fXII-deficient mice are resistant to ferric chloride-induced arterial thrombosis, and this resistance can be reversed by infusion of human fXII. 9A2 partially blocks, and 15H8 completely blocks, the prothrombotic effect of fXII in this model. 15H8 prolonged the activated partial thromboplastin time of baboon and human plasmas. 15H8 reduced fibrin formation in collagen-coated vascular grafts inserted into arteriovenous shunts in baboons, and reduced fibrin and platelet accumulation downstream of the graft. These findings support a role for fXII in thrombus formation in primates.

    UR - http://www.scopus.com/inward/record.url?scp=84897538637&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84897538637&partnerID=8YFLogxK

    U2 - 10.1182/blood-2013-04-499111

    DO - 10.1182/blood-2013-04-499111

    M3 - Article

    C2 - 24408325

    AN - SCOPUS:84897538637

    VL - 123

    SP - 1739

    EP - 1746

    JO - Blood

    JF - Blood

    SN - 0006-4971

    IS - 11

    ER -